Thomas Smith

Thomas Smith

Analyst-Equity presso Leerink Partners LLC

Finance
Technology Services
Consumer Services

Profilo

Mr. Thomas J.
Smith
is a Senior Managing Director of Immunology & Metabolism at Leerink Partners LLC.
He is also a Senior Research Analyst covering Immunology and Metabolism.
Prior to covering the Immunology and Metabolism sector, Mr. Smith was a key member of Leerink Partners’ Targeted Oncology team helping to deliver in-depth fundamental research to clients.
Prior to joining the firm in 2018, he was most recently a Vice President and Research Analyst at Morgan Stanley, covering leading and emerging biopharmaceutical companies across numerous therapeutic areas, including oncology, NASH, and lead coverage of women’s health companies.
Prior to that, he worked at FBR Capital Markets on the biotechnology team, responsible for coverage of large, mid-, and small cap companies.
Mr. Smith began his career at Bloomberg where he held roles of increasing responsibility, including coverage of the biotech and specialty pharmaceutical sectors for Bloomberg Intelligence.
He earned his B.S.
in Finance and Psychology from The College of New Jersey.

Posizioni attive di Thomas Smith

SocietàPosizioneInizio
Analyst-Equity 01/05/2018
Tutte le posizioni attive di Thomas Smith

Precedenti posizioni note di Thomas Smith

SocietàPosizioneFine
Analyst-Equity 01/05/2018
Analyst-Equity 31/12/2014
Corporate Officer/Principal 30/04/2014
Corporate Officer/Principal 31/05/2007
Vedi nel dettaglio l'esperienza di Thomas Smith

Formazione di Thomas Smith

The College of New Jersey Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Thomas Smith

Relazioni

99

Relazioni di 1° grado

6

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private5

Finance

Technology Services

Finance

Finance

Finance

Vedi le connessioni aziendali
-40% Offerta a tempo limitato: i nostri abbonamenti ti guidano verso i migliori investimenti di domani.
APPROFITTANE ORA